The proportion of HER2-low breast cancer was higher in patients with HR-positive breast cancer than in those with TNBC: 7,910 (33.6%) in HR-positive breast cancer and 1,594 (23.0%) in TNBC (P < 0.001). Here, ERBB2 is linked to breast carcinoma.